

Diwakar R Pattabiraman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3553572/publications.pdf>

Version: 2024-02-01

21
papers

5,858
citations

471061

17
h-index

752256

20
g-index

23
all docs

23
docs citations

23
times ranked

12658
citing authors

#	ARTICLE	IF	CITATIONS
1	Quantifying the Epithelial-to-Mesenchymal Transition (EMT) from Bench to Bedside. <i>Cancers</i> , 2022, 14, 1138.	1.7	11
2	Distinct cytosine modification profiles define epithelial-to-mesenchymal cell-state transitions. <i>Epigenomics</i> , 2022, 14, 519-535.	1.0	4
3	Limiting Self-Renewal of the Basal Compartment by PKA Activation Induces Differentiation and Alters the Evolution of Mammary Tumors. <i>Developmental Cell</i> , 2020, 55, 544-557.e6.	3.1	20
4	Endothelial E-selectin inhibition improves acute myeloid leukaemia therapy by disrupting vascular niche-mediated chemoresistance. <i>Nature Communications</i> , 2020, 11, 2042.	5.8	99
5	The systemic response to surgery triggers the outgrowth of distant immune-controlled tumors in mouse models of dormancy. <i>Science Translational Medicine</i> , 2018, 10, .	5.8	301
6	Recovering Gene Interactions from Single-Cell Data Using Data Diffusion. <i>Cell</i> , 2018, 174, 716-729.e27.	13.5	1,197
7	Emerging Biological Principles of Metastasis. <i>Cell</i> , 2017, 168, 670-691.	13.5	2,208
8	Integrin- α 24 identifies cancer stem cell-enriched populations of partially mesenchymal carcinoma cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, E2337-E2346.	3.3	273
9	Targeting the Epithelial-to-Mesenchymal Transition: The Case for Differentiation-Based Therapy. <i>Cold Spring Harbor Symposia on Quantitative Biology</i> , 2016, 81, 11-19.	2.0	51
10	Activation of PKA leads to mesenchymal-to-epithelial transition and loss of tumor-initiating ability. <i>Science</i> , 2016, 351, aad3680.	6.0	271
11	Hypoxia inducible factor (HIF)- 2α accelerates disease progression in mouse models of leukemia and lymphoma but is not a poor prognosis factor in human AML. <i>Leukemia</i> , 2015, 29, 2075-2085.	3.3	36
12	Interaction of c-Myb with p300 is required for the induction of acute myeloid leukemia (AML) by human AML oncogenes. <i>Blood</i> , 2014, 123, 2682-2690.	0.6	103
13	Tackling the cancer stem cells "what challenges do they pose?". <i>Nature Reviews Drug Discovery</i> , 2014, 13, 497-512.	21.5	831
14	Vascular Niche E-Selectin Protects Acute Myeloid Leukaemia Stem Cells from Chemotherapy. <i>Blood</i> , 2014, 124, 620-620.	0.6	20
15	Role and potential for therapeutic targeting of MYB in leukemia. <i>Leukemia</i> , 2013, 27, 269-277.	3.3	110
16	miR-139-5p is a regulator of metastatic pathways in breast cancer. <i>Rna</i> , 2013, 19, 1767-1780.	1.6	137
17	A functional SUMO-interacting motif in the transactivation domain of c-Myb regulates its myeloid transforming ability. <i>Oncogene</i> , 2011, 30, 212-222.	2.6	21
18	Integrated genome-wide chromatin occupancy and expression analyses identify key myeloid pro-differentiation transcription factors repressed by Myb. <i>Nucleic Acids Research</i> , 2011, 39, 4664-4679.	6.5	89

#	ARTICLE	IF	CITATIONS
19	A recessive screen for genes regulating hematopoietic stem cells. <i>Blood</i> , 2010, 116, 5849-5858.	0.6	27
20	Mutations in Multiple Domains of c-Myb Disrupt Interaction with CBP/p300 and Abrogate Myeloid Transforming Ability. <i>Molecular Cancer Research</i> , 2009, 7, 1477-1486.	1.5	34
21	Identification of Novel MYB Target Genes. <i>Blood</i> , 2008, 112, 3580-3580.	0.6	0